Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A newly identified or characterized cell surface receptor belonging to the TREM family, expressed on antigen-presenting cells (APCs) such as dendritic cells and macrophages, as well as some lymphoid cells. It acts as an activating receptor, enhancing antigen presentation capabilities and modulating downstream immune responses upon ligand binding. Downstream signaling involves adapter proteins like DAP12, leading to phosphorylation cascades and gene transcription relevant for inflammation or tolerance. Understanding its specific ligands and signaling pathways could have implications for vaccine development and modulating autoimmune responses.
Ligand binding induces activation signals via adapter proteins (e.g., DAP12) leading to phosphorylation cascades and gene transcription relevant for inflammation or tolerance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel Triggering Receptor Expressed on Myeloid Cells (TREM) Family Member (Novel TREM Receptor).